4DMT Announces New Employment Inducement Grants

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced on November 14, 2025 that its compensation committee granted 45,400 restricted stock units (RSUs) on November 11, 2025 to four new non-executive employees.

The awards were made under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 pursuant to Nasdaq Rule 5635(c)(4) to induce new hires to join the company.

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 11, 2025, the compensation committee of the Company’s board of directors granted four new non-executive employees 45,400 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

What did 4D Molecular Therapeutics (FDMT) announce on November 14, 2025?

The company announced the grant of 45,400 RSUs on November 11, 2025 to four new non-executive employees.

How many employees received RSU inducement grants from FDMT on November 11, 2025?

Four new non-executive employees received inducement RSU grants.

Under which plan were the FDMT RSUs granted and when was it approved?

The RSUs were granted under the 2025 Employment Inducement Award Plan, approved by the board in February 2025.

What Nasdaq rule authorized FDMT’s inducement awards?

The grants were made pursuant to Nasdaq Rule 5635(c)(4), which permits equity inducement awards for new employees.

How many RSUs did 4DMT grant in total on November 11, 2025?

A total of 45,400 restricted stock units were granted.

Do the November 11, 2025 RSU grants represent executive compensation at FDMT?

No; the grants were given to non-executive employees as inducement awards.